drugset / Trial / NCT00275548
Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C
RandomizedParallel-groupOpen-labelPrevention
Summary
The study is being done to study the impact of prophylactic administration of antiviral therapy as compared to initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection in liver transplant recipients.
Timeline
- Start
- 2004-07
- Primary completion
- 2007-06
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 135 ug | Subcutaneous |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Subject | Ribavirin | Small molecule | 400 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |